Beckman Coulter, Inc. announced that it has initially been awarded a contract of $1.25 million, with potential to be awarded an additional $6.5 million if all contract options are exercised, from the DRIVe (Division of Research, Innovation, and Ventures) established by the Biomedical Advanced Research and Development Authority (BARDA), under the Office of the Assistant Secretary for Preparedness…
Spanish researchers in Valencia have identified specific fragments of genetic material that play a role in the development of respiratory failure and sepsis in pneumonia patients. Presenting the research at the European Respiratory Society International Congress, Dr Francisco Sanz said the findings could enable doctors to test quickly for these biological markers when a patient is admitted to…
The critical element of testing for sepsis lies not so much in the location but in the timing and rapidity of results, according to Professor Jeannine T. Holden from Beckman Coulter Early identification enables treatment protocols to be delivered more quickly, offering better patient outcomes. Those most at risk, suggests Holden, are not patients within the intensive care unit – who are already…
A major milestone on its strategic mission to lead in sepsis diagnostics, Beckman Coulter announced that its Early Sepsis Indicator has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Sepsis is a global healthcare crisis that affects more than 30 million people worldwide. The Early Sepsis Indicator is a first-of-its-kind, hematology-based cellular biomarker that is…
Beckman Coulter, a global leader in clinical diagnostics will be demonstrating its latest comprehensive solutions in microbiology, urinalysis and hematology at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). During the conference, Beckman Coulter is also hosting a symposium where attendees will learn how the laboratory can help physicians detect…
T2 Biosystems, maker of rapid diagnostic technology to aid in the detection of blood stream infections to prevent sepsis, will host an integrated symposium titled “Rapid Diagnostics Direct from Whole Blood: A Solution for Fast and Appropriate Antimicrobial Therapy,” at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, Monday, April 15, 16:00-18:00…
Researchers at the University of Strathclyde have developed an innovative, low cost test for earlier diagnosis of sepsis which could save thousands of lives. The simple system for sensitive real-time measurement of the life threatening condition is much quicker than existing hospital tests, which can take up to 72 hours to process. Using a microelectrode, a biosensor device is used to detect if…
Sepsis remains a common and deadly condition that occurs when the body reacts to an infection in the bloodstream. Scientists know little about the early stages of the condition; however, physicians must act fast. Every hour that passes without one or more of the few treatments available increases the risk of death.
Beckman Coulter was a gold sponsor of the 2nd World Sepsis Congress, a free-of-charge online conference, hosted by the Global Sepsis Alliance, that took place on Sept. 5 and 6, 2018. Over the course of 17 sessions, more than 100 speakers from approximately 30 countries discussed the wide-ranging implications of sepsis and how to raise public awareness of this often-fatal condition.
More than a million neonatal deaths worldwide each year are estimated to be due to sepsis. In the UK there are approximately 90,000 admissions to neonatal intensive care units per year. Nearly all these patients receive antibiotic therapy during their hospital stay, but babies with a specific genetic change can suffer irreversible hearing loss as a result. Now, in a collaboration between…
Beckman Coulter announced its exclusive sponsorship of the ESCAVO Sepsis Clinical Guide (Sepsis app), a point-of-care medical reference mobile application for healthcare professionals who manage septic patients in acute-care settings. Beckman Coulter’s sponsorship of the Sepsis app ensures that the tool will remain free for all users and that content will continue to be maintained and updated…
In continuation of Radiometer’s commitment to the fight against sepsis – one of the world’s deadliest diseases - Radiometer is proud to sponsor World Sepsis Day for the second consecutive year.
Beckman Coulter Diagnostics along with partner Diazyme Laboratories announces FDA clearance of a new procalcitonin (PCT) assay, an important tool for the management of bacterial infections and sepsis.
A machine-learning algorithm has the capability to identify hospitalized patients at risk for severe sepsis and septic shock using data from electronic health records (EHRs), according to a study presented at the 2017 American Thoracic Society International Conference. Sepsis is an extreme systemic response to infection, which can be life-threatening in its advanced stages of severe sepsis and…
New criteria used as an initial screening tool in the emergency department need to be re-evaluated, a specialised surgeon highlighted in a dedicated talk during the Spanish national congress of surgery this November.
The UK’s first dedicated emergency department sepsis team has been set up in one of the country’s leading hospitals. Leicester Hospital’s created the team to recognise and manage sepsis. The key aim is to strengthen the response, in a timely manner, to sepsis cases admitted to the emergency department or to identify rapidly any patients who deteriorate within the unit.
Recommendations on the currently valid prevention of intravascular catheter-related infections from the Commission for Hospital Hygiene and Infection Prevention at the Robert Koch-Institute (KRINKO) are now 14 years old and therefore out-dated.
Abionic SA announced the receipt of CE Mark (Conformité Européenne) for two novel tests using its easy to use testing platform, abioSCOPE. The CE Mark allows Abionic to commercialize its tests for sepsis risk assessment and management (PSP Test) and iron deficiency throughout the European Union.
Magnets instead of antibiotics could provide a possible new treatment method for blood infection. This involves the blood of patients being mixed with magnetic iron particles, which bind the bacteria to them after which they are removed from the blood using magnets. The initial laboratory tests at Empa in St. Gallen have been successful, and seem promising.
What do Casey Kasem, Christopher Reeve and Muhammad Ali have in common? They all died of sepsis: a rapid, potentially deadly reaction that affects millions each year.
No one knows for sure how they got there. But the discovery that bacteria that normally live in the gut can be detected in the lungs of critically ill people and animals could mean a lot for intensive care patients.
Most people recoil at the thought of ingesting E. coli. But what if the headline-grabbing bacteria could be used to fight disease? Researchers experimenting with harmless strains of E. coli — yes, the majority of E. coli are safe and important to healthy human digestion — are working toward that goal. They have developed an E. coli-based transport capsule designed to help next-generation…
Bacterial infections that don't respond to antibiotics are of rising concern, as is sepsis - the immune system's last-ditch, failed attack on infection that ends up being lethal itself. Reporting online in "Nature", researchers at Boston Children's Hospital describe new potential avenues for controlling both sepsis and the runaway bacterial infections that provoke it.
Sepsis represents a serious complication of infection and is one of the leading causes of death and critical illness worldwide due in part to the lack of effective therapies.
Since 2009, as part of diagnostic and antimicrobial stewardship strategies, Hampshire Hospitals National Health Service (NHS) Trust has used serum procalcitonin (PCT) – an innovative and highly specific marker to diagnose clinically relevant bacterial infections and sepsis. Report: Mark Nicholls